U79-24385-10388
4 vaccinations
1 coded response
31 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 282 / NC
- Registered
- 2021-01-28
- Relationship
- Self
- Race
- Multiracial
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-27
Dose 1 — Pfizer-BioNTech
-
2021-01-28
Registered in v-safe
-
2021-01-28
Health check-in — days 1–6 daily, dose 1Feeling: Poor · Site: Pain, Itching · Fever · Headache, Joint pains, Muscle or body aches, Fatigue or tiredness, NauseaAdult check-in
-
2021-01-29
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Site: Pain · Muscle or body aches, Fatigue or tirednessAdult check-in
-
2021-01-30
Health check-in — days 1–6 daily, dose 1Feeling: Good · Site: Pain, Itching · Headache, Fatigue or tirednessAdult check-in
- 2021-01-31
-
2021-02-01
Health check-in — days 1–6 daily, dose 1Feeling: Good · Muscle or body aches, Fatigue or tirednessAdult check-in
- 2021-02-02
- 2021-02-03
- 2021-02-10
-
2021-02-19
Dose 2 — Pfizer-BioNTech
- 2021-02-24
- 2021-02-25
- 2021-02-27
- 2021-03-05
- 2021-03-12
- 2021-04-04
- 2021-05-21
- 2021-08-20
-
2022-02-19
Survey response — 12 months, dose 2MedDRA: Abdominal distension, Asthenia, Decreased appetite, Diarrhoea, Gastrointestinal disorder, Heart rate increased, Lactose intolerance, Total lung capacity decreased — Feeling: Good · Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Continued elevated heart rate continued low stamina with exercise continued diminished lung capacity/inhaler use. New GI issues- diminished hunger and fullness cues, now lactose intolerant, Diherrea on and offMedDRA releases: 2024-11 · check-in free text available
-
2022-02-19
Report sent to call center — 12 months, dose 2Get care from a doctor or other healthcare professionalOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-02-22
-
2022-02-22
Call successfulDoes not wish to fill out VAERS report
-
2022-05-17
Dose 3 — Pfizer-BioNTech
-
2022-10-17
Dose 4 — Pfizer-BioNTech
-
2022-10-17
Health check-in — day 0, dose 4Feeling: Fair · Site: Pain · Joint pains, Muscle or body aches, Fatigue or tiredness, Abdominal painAdult check-in
-
2022-10-18
Health check-in — days 1–6 daily, dose 4Feeling: Fair · Site: Pain · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
-
2022-10-19
Health check-in — days 1–6 daily, dose 4Feeling: Good · Site: Pain · Headache, Fatigue or tirednessAdult check-in
- 2022-10-20
- 2022-10-21
- 2022-10-22
- 2022-10-23
- 2022-10-24
- 2022-11-07
- 2022-11-14
- 2022-11-23
- 2022-11-28
- 2023-01-19
- 2023-04-17
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-27 | Pfizer-BioNTech | |
| 2 | 2021-02-19 | Pfizer-BioNTech | |
| 3 | 2022-05-17 | Pfizer-BioNTech | No |
| 4 | 2022-10-17 | Pfizer-BioNTech | No |
Call center
1 call center case
1 successful
Free text
Release 11 — 12 months, dose 2
Symptoms: Continued elevated heart rate continued low stamina with exercise continued diminished lung capacity/inhaler use. New GI issues- diminished hunger and fullness cues, now lactose intolerant, Diherrea on and off
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Abdominal distension | · | · | ✓ |
| SD | Asthenia | · | · | ✓ |
| SD | Decreased appetite | · | · | ✓ |
| SD | Diarrhoea | · | · | ✓ |
| SD | Gastrointestinal disorder | · | · | ✓ |
| SD | Heart rate increased | · | · | ✓ |
| SD | Lactose intolerance | · | · | ✓ |
| SD | Total lung capacity decreased | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release